#Japan #Tokyo #Gellycle #TetraGel #Soken Chemical

Gellycle and Soken Chemical in Partnership for Cell Culture Innovations

In a significant move towards advancing cell culture technologies, Gellycle Co., Ltd., a Tokyo University spin-off biotech company, has entered into a collaborative development agreement with Soken Chemical & Engineering Co., Ltd. This partnership aims to explore new product development possibilities within the domain of cell culture utilizing the unique properties of TetraGel, Gellycle's proprietary gel technology.

As the fields of regenerative medicine and drug development continue to grow, the importance of effective cell culture techniques becomes paramount. Traditional methods face various challenges, including the difficulty of maintaining cell functionality during large-scale cultures, achieving desired cell differentiation, and sustaining three-dimensional structures in cultures. These hurdles pose significant barriers to supplying high-quality cells consistently, accomplishing accurate drug efficacy evaluations in environments mimicking biological conditions, and utilizing cultured cells in future tissue and organ regeneration through transplantation.

The collaboration between Gellycle and Soken Chemical seeks to address these challenges by leveraging Gellycle's innovative TetraGel technology to develop more efficient and higher-performing cell culture products. The goal is to contribute to advancements in regenerative medicine and drug development while unlocking new potential within the life sciences sector.

Gellycle aims to expedite the introduction of new cell culture-related products to the market. With expertise in polymer design and mass production technology, Soken Chemical brings valuable capabilities to this partnership, which will focus on rapid development and swift market entry.

Comments from Gellycle’s Representative

Kousuke Masui, the CEO of Gellycle, expressed his excitement regarding the partnership with Soken Chemical. He stated, "We are honored to formalize this collaboration. By integrating Gellycle's advanced gel technologies with Soken Chemical's comprehensive materials development knowledge and proven expertise in the cell culture realm, we are confident in our ability to create truly innovative cell culture products that have never been seen before. Through this collaboration, we aim to enhance the advancement of regenerative medicine and drug development, thereby providing new opportunities within the life sciences field."

About Gellycle Co., Ltd.

Founded in 2018, Gellycle is a biotech startup from Tokyo University focused on innovating the medical field using TetraGel, the world's only uniform gel. The company is dedicated to developing various medical products, including hemostatic agents, adhesion prevention materials, and tendon regeneration products. Gellycle envisions a future where diseases can be treated simply by injecting gel. Notably, the company has received accolades including winning the ICC Summit KYOTO 2021 Real Tech Catapult and being awarded the 2023 Special Prize for University-based Ventures.

About Soken Chemical & Engineering Co., Ltd.

Established in 1948, Soken Chemical specializes in manufacturing and selling functional polymers, organic fine particles, and adhesive products, such as acrylic adhesives. Their products are widely used in consumer electronics, automotive applications, and more, dominating market shares, particularly with adhesives for liquid crystal panel installations. Soken Chemical leverages its strengths within its group, particularly through the subsidiary Soken Technics, to develop high-quality, cost-effective production systems from equipment design to implementation.

For more information about Gellycle and technological inquiries, please contact:

• - Sales Department

Email: [email protected]

As both companies embark on this journey, they stand poised to push the boundaries of innovation within the cell culture and life sciences sectors, making significant strides toward better solutions for regenerative medicine and drug discovery.